NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR)

 
AVNR Technical Analysis
5
As on 12th Jan 2015 AVNR Share Price closed @ 16.96 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 7.96 & Strong Buy for SHORT-TERM with Stoploss of 15.12 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

AVNR Share Price

Open 16.96 Change Price %
High 16.98 1 Day 0.00 0.00
Low 16.96 1 Week 0.00 0.00
Close 16.96 1 Month 0.00 0.00
Volume 8430307 1 Year 0.00 0.00
52 Week High 6.07 | 52 Week Low 3.99
 
NASDAQ USA Most Active Stocks
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
MU 44.31 6.39%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
INTC 45.49 2.52%
 
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
SCHS 0.04 33.33%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
HLIT 3.70 25.42%
OTT 2.39 25.13%
QNST 8.90 20.76%
VRTA 4.00 19.40%
SNSS 2.56 19.07%
GCFB 0.44 18.92%
 
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
GMETP 0.15 -76.92%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
 
 
AVNR
Daily Charts
AVNR
Intraday Charts
Whats New @
Bazaartrend
AVNR
Free Analysis
 
AVNR Important Levels Intraday
SUPPORT0.00
SUPPORT0.00
RESISTANCE16.98
RESISTANCE16.97
SUPPORT16.95
SUPPORT16.94
SUPPORT0.00
SUPPORT0.00
 
AVNR Target for Month October
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
AVNR Weekly Target
4th UP TARGET0.00
3rd UP TARGET0.00
2nd UP TARGET0.00
1st UP TARGET0.00
1st DOWN TARGET0.00
2nd DOWN TARGET0.00
3rd DOWN TARGET0.00
4th DOWN TARGET0.00
 
AVNR Target for Year 2020
4th UP TARGET0
3rd UP TARGET0
2nd UP TARGET0
1st UP TARGET0
1st DOWN TARGET0
2nd DOWN TARGET0
3rd DOWN TARGET0
4th DOWN TARGET0
 
 
AVNR Other Details
Segment EQ
Market Capital 369051584.00
Sector Healthcare
Industry Drugs - Generic
Offical website >
 
AVNR Address
AVNR
20 Enterprise
Suite 200
Aliso Viejo, CA 92656
United States
Phone: 949-389-6700
Fax: 949-389-6701
 
AVNR Latest News
 
Your Comments and Response on Avanir Pharmaceuticals, Inc.
 
AVNR Business Profile
AVANIR Pharmaceuticals, Inc. (AVANIR), incorporated in August 1998, is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA). In October 2010, FDA approved NUEDEXTA, is a combination of dextromethorphan/quinidine, for the treatment of pseudobulbar affect (PBA). NUEDEXTA is the FDA-approved treatment for PBA, which occurs secondary to a range of neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes occur out of proportion or incongruent to the patient’s underlying emotional state. NUEDEXTA is a combination of two components: dextromethorphan hydrobromide, the ingredient active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and N-Methyl-D-aspartic acid (NMDA), receptors in the brain. Diabetic peripheral neuropathic pain (DPN pain), which arises from nerve injury, can result in a chronic and debilitating form of pain. AVANIR has completed a Phase III clinical trial for AVP-923 in the treatment of patients with DPN pain. AVP-923 also demonstrated improvements in a number of key secondary endpoints, including the pain relief ratings scale and the pain intensity ratings scale. In September 2009, it reported on secondary efficacy endpoints from the double-blind phase of the AVP-923 STAR trail in PBA, including an endpoint measuring reduction of pain in patients with underlying multiple sclerosis (MS).
 
© 2005-2019 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service